Intellia Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
08/05/2025 14:31
Intellia Therapeutics Inc NTLA.OQ reported a quarterly adjusted loss of $1.10 per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of $-1.12. The mean expectation of twenty two analysts for the quarter was for a loss of $1.28 per share. Wall Street expected results to range from $-1.49 to -89 cents per share. Revenue fell 42.5% to $16.63 million from a year ago; analysts expected $11.87 million. Intellia Therapeutics Inc's reported EPS for the quarter was a loss of $1.10. The company reported a quarterly loss of $114.33 million. Intellia Therapeutics Inc shares had risen by 2.5% this quarter and lost 37.5% so far this year. FORECAST CHANGES The mean earnings estimate of analysts had risen by about 5.1% in the last three months. In the last 30 days, one analyst negatively revised an earnings estimate RECOMMENDATIONS The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 21 "strong buy" or "buy," 6 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" Wall Street's median 12-month price target for Intellia Therapeutics Inc is $41.00 This summary was machine generated from LSEG data May 8 at 01:31 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Mar. 31 2025 | -1.28 | -1.10 | Beat |
| Dec. 31 2024 | -1.33 | -1.27 | Beat |
| Sep. 30 2024 | -1.38 | -1.34 | Beat |
| Jun. 30 2024 | -1.23 | -1.52 | Missed |
Recent news on INTELLIA THERAPEUTICS
See all newsU.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple
U.S. STOCKS ON THE MOVE-Qualcomm, Eaton, Howmet Aerospace
U.S. STOCKS ON THE MOVE-Sigma Lithium, Shake Shack, Novartis
Intellia rises after FDA grants fast-track status to its treatment for rare disease
Brief: Intellia Therapeutics Announces FDA Acceptance Of Biologics License Application With Priority Review For Lonvoguran Ziclumeran (Lonvo-Z) For Hereditary Angioedema (Hae)